Iterum Therapeutics Regains Full Nasdaq Compliance
November 21, 2024 08:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat...
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
November 14, 2024 07:00 ET
|
Iterum Therapeutics PLC
-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
November 11, 2024 08:00 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections...
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
October 25, 2024 11:03 ET
|
Iterum Therapeutics PLC
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th...
Iterum Therapeutics to Present Data at IDWeek 2024
October 10, 2024 08:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
October 09, 2024 17:00 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics...
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
September 10, 2024 07:00 ET
|
Iterum Therapeutics PLC
FDA Decision Expected by PDUFA Goal Date of October 25, 2024 Potential to be First Oral Penem Approved in the U.S. DUBLIN and CHICAGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
September 06, 2024 16:30 ET
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral...
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
August 14, 2024 07:00 ET
|
Iterum Therapeutics PLC
-- FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— --Cash Runway into 2025, including through PDUFA Action Date-- --Company to Host Conference Call...
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
August 07, 2024 16:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...